Dr Azeem Saleem


Reader and Honorary Consultant in Clinical Oncology

Role at Hull York Medical School

Dr Azeem Saleem is a Reader at the University of Hull and a Honorary Consultant in Clinical Oncology at the Queen's Centre, Castle Hill Hospital.


Dr Azeem Saleem is a Clinical Oncologist by training with a research background in molecular imaging with wide experience in industry and academia. He obtained his medical qualification (MB BS) in 1988 from Madras University, India and did his research fellowship at the Medical Research Council (MRC) Cyclotron Unit, Hammersmith Hospital, London between 1997 and 2000, evaluating the utility of positron emission tomography (PET) in anti-cancer drug development to obtain his PhD.

He then went on to complete his specialist training in Clinical Oncology at Merseyside. He was appointed as a Senior Clinical Research Fellow at the University of Manchester Wolfson Molecular Imaging Centre and an Honorary Consultant in Clinical Oncology at the Christie Hospital in 2005. In 2009, he joined the GlaxoSmithKline Clinical Imaging Centre at the Hammersmith Hospital to lead the oncology imaging programme and as an honorary senior clinical lecturer at Imperial College. From 2011 to 2017, he headed oncology and respiratory medicine applications at Imanova Centre for Imaging Sciences, an Imperial College, University College London, Kings College London and MRC joint venture which aimed to provide imaging expertise to academia and commercial organisations. From 2018, he was the UK Head of Oncology at Invicro, a Konica Minolta Company. He joined the University of Hull in December 2019.


Dr Saleem's area of research is translational molecular (PET and MR) imaging studies in oncology. First in human clinical studies with novel PET radiotracers and novel drug assets. Radiotherapy and clinical oncology studies.


View Dr Saleem's full publications list here.

Helo, Y., Searle, G.E., Borghese, F., Abraham, S., Saleem, A. Specificity of translocator protein-targeted positron emission tomography in inflammatory joint disease. EJNMMI Res 10, 147 (2020). https://doi.org/10.1186/s13550-020-00736-9

Advanced imaging for quantification of abnormalities in the salivary glands of patients with primary Sjögren's syndrome.  PMID: 33221921 DOI: 10.1093/rheumatology/keaa624

A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor. Respir Res. 2020 Mar 26;21(1):75. doi: 10.1186/s12931-020-01339-7. Maher TM, Simpson JK, Porter JC, Wilson FJ, Chan R, Eames R, Cui Y, Siederer S, Parry S, Kenny J, Slack RJ, Sahota J, Paul L, Saunders P, Molyneaux PL, Lukey PT, Rizzo G, Searle GE, Marshall RP, Saleem A, Kang'ombe AR, Fairman D, Fahy WA, Vahdati-Bolouri M. 

Integrin αvβ6 positron emission tomography imaging in lung cancer patients treated with pulmonary radiotherapy. Int J Rad Oncol Biol Physics. 2020 Feb 11. pii: S0360-3016(20)30184-X. doi: 10.1016/j.ijrobp.2020.02.014. 

Fluorothymidine Positron Emission Tomography (FLT-PET) Repeatability and Response Evaluation in Advanced Pancreatic Cancer Patients Treated with Gemcitabine-Based Chemotherapy. Clinical Oncology and Research. 2019. DOI: 10.31487/j.COR.2019.5.17 

Lukey PT, Coello C, Gunn R, Parker C, Wilson FJ, Saleem A, Garman N, Costa M, Kendrick S, Onega M, Kang'ombe AR, Listanco A, Davies J, Ramada-Magalhaes J, Moz S, Fahy WA, Maher TM, Jenkins G, Passchier J, Marshall RP. Clinicalquantification of the integrin αvβ6 by [(18)F]FB-A20FMDV2 positron emissiontomography in healthy and fibrotic human lung (PETAL Study). Eur J Nucl Med MolImaging. 2019 Dec 9. doi: 10.1007/s00259-019-04586-z. [Epub ahead of print]PubMed PMID: 31814068.

Erritzoe D, Ashok AH, Searle GE, Colasanti A, Turton S, Lewis Y, Huiban M, MozS, Passchier J, Saleem A, Beaver J, Lingford-Hughes A, Nutt DJ, Howes OD, GunnRN, Knudsen GM, Rabiner EA. Serotonin release measured in the human brain: a PET study with [(11)C]CIMBI-36 and d-amphetamine challenge. Neuropsychopharmacology. 2019 Nov 12. doi: 10.1038/s41386-019-0567-5. [Epub ahead of print] PubMed PMID:31715617.

Brown NF, Williams M, Arkenau HT, Fleming RA, Tolson J, Yan L, Zhang J, SwartzL, Singh R, Auger KR, Lenox L, Cox D, Lewis Y, Plisson C, Searle G, Saleem A,Blagden S, Mulholland P. A study of the focal adhesion kinase inhibitorGSK2256098 in patients with recurrent glioblastoma with evaluation of tumorpenetration of [11C]GSK2256098. Neuro Oncol. 2018 Nov 12;20(12):1634-1642. doi:10.1093/neuonc/noy078. PubMed PMID: 29788497; PubMed Central PMCID: PMC6231205.

Keat N, Kenny J, Chen K, Onega M, Garman N, Slack RJ, Parker CA, Lumbers RT,Hallett W, Saleem A, Passchier J, Lukey PT. A Microdose PET Study of the Safety, Immunogenicity, Biodistribution, and Radiation Dosimetry of (18)F-FB-A20FMDV2 forImaging the Integrin α(v)β(6). J Nucl Med Technol. 2018 Jun;46(2):136-143. doi:10.2967/jnmt.117.203547. Epub 2018 Feb 2. PubMed PMID: 29438002.

Narayan N, Owen DR, Mandhair H, Smyth E, Carlucci F, Saleem A, Gunn RN,Rabiner EA, Wells L, Dakin SG, Sabokbar A, Taylor PC. Translocator Protein as an Imaging Marker of Macrophage and Stromal Activation in Rheumatoid ArthritisPannus. J Nucl Med. 2018 Jul;59(7):1125-1132. doi: 10.2967/jnumed.117.202200.Epub 2018 Jan 4. PubMed PMID: 29301931.

Dubash SR, Keat N, Mapelli P, Twyman F, Carroll L, Kozlowski K, Al-Nahhas A,Saleem A, Huiban M, Janisch R, Frilling A, Sharma R, Aboagye EO. ClinicalTranslation of a Click-Labeled 18F-Octreotate Radioligand for ImagingNeuroendocrine Tumors. J Nucl Med. 2016 Aug;57(8):1207-13. doi:10.2967/jnumed.115.169532. Epub 2016 May 12. PubMed PMID: 27173162.

Gungor H, Saleem A, Babar S, Dina R, El-Bahrawy MA, Curry E, Rama N, Chen M,Pickford E, Agarwal R, Blagden S, Carme S, Salinas C, Madison S, Krachey E,Santiago-Walker A, Smith DA, Morris SR, Stronach EA, Gabra H. Dose-FindingQuantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795in Patients with Gynecologic Malignancies. J Nucl Med. 2015 Dec;56(12):1828-35.doi: 10.2967/jnumed.115.156505. Epub 2015 Oct 1. PubMed PMID: 26429956.

Saleem A, Searle GE, Kenny LM, Huiban M, Kozlowski K, Waldman AD, Woodley L,Palmieri C, Lowdell C, Kaneko T, Murphy PS, Lau MR, Aboagye EO, Coombes RC.Lapatinib access into normal brain and brain metastases in patients with Her-2overexpressing breast cancer. EJNMMI Res. 2015 Apr 30;5:30. doi:10.1186/s13550-015-0103-5. eCollection 2015. Erratum in: EJNMMI Res. 2017 Sep8;7(1):74. EJNMMI Res. 2017 Sep 18;7(1):76. PubMed PMID: 25977884; PubMed CentralPMCID: PMC4424224.

Rembielak AI, Jain P, Jackson AS, Green MM, Santorelli GR, Whitfield GA,Crellin A, Garcia-Alonso A, Radhakrishna G, Cullen J, Taylor MB, Swindell R, WestCM, Valle J, Saleem A, Price PM. Phase II Trial of Cetuximab and ConformalRadiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent TissueSampling Feasibility Study. Transl Oncol. 2014 Feb 1;7(1):55-64. eCollection 2014Feb. PubMed PMID: 24772208; PubMed Central PMCID: PMC3998695.

Talbot DC, Ranson M, Davies J, Lahn M, Callies S, André V, Kadam S, BurgessM, Slapak C, Olsen AL, McHugh PJ, de Bono JS, Matthews J, Saleem A, Price P.Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: aproof-of-concept, first-in-human dose study. Clin Cancer Res. 2010 Dec15;16(24):6150-8. doi: 10.1158/1078-0432.CCR-10-1932. Epub 2010 Nov 1. Erratumin: Clin Cancer Res. 2011 Apr 15;17(8):2602. PubMed PMID: 21041181.